Jan 16 (Reuters) - The U.S. Food and Drug Administration approved Amgen's (AMGN.O), opens new tab combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.

Today’s Green deals are bringing you three flash sales with some big savings – two on e-bikes, one on power stations. Leading the group is Rad Power’s flash sale with two end dates (January ...

His career has included stops at Eli Lilly, Novian Health and, for the last 16 years, Amgen. His tenure at Amgen included roles in sales and marketing for many of its hematology and oncology ...

In a report released today, Srikripa Devarakonda from Truist Financial assigned a Hold rating to Amgen (AMGN – Research Report). The company’s shares closed yesterday at $267.10. Discover ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report), retaining the price target of $362.00. Discover outperforming stocks and invest smarter with Top ...

the company later explained that OpenELM was an open-source model created for research purposes and that its database is not used to power Apple Intelligence. According to Apple, its AI features ...

THOUSAND OAKS, Calif., Jan. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January ...